Portfolio company
Rejuvenate Biomed
Belgium · £13.3m raised
Raised
£13.3m
Latest stage
Series B
Rounds recorded
1
Backed by
2 investors
Sectors
About
This biotech company develops AI-enabled prescription combination drugs to treat age-related diseases and muscle decline in older patients.
SourceFunding history · 1
Similar companies
Rejuvenate Biomed NV
This clinical-stage biotechnology company develops combination therapeutics for patients with age-related diseases, focusing on muscle weakness and sarcopenia using artificial intelligence discovery platforms.
Shift Bioscience
This biotechnology company develops cellular rejuvenation therapeutics and an AI-driven discovery platform for pharmaceutical researchers to treat age-related diseases.
Rejuveron
This biotechnology firm develops medicines and regenerative therapies targeting age-related diseases to improve healthspan for the aging population.
BioAge Labs
This company develops therapeutic drugs targeting the biology of human aging to treat patients with metabolic and cardiovascular diseases.
TURN BIO
This biotechnology company develops mRNA-based medicines to rejuvenate cells and treat age-related conditions for patients with dermatological, immunological, and osteoarthritic diseases.
Juvena Therapeutics
This biotechnology company develops protein-based regenerative medicines for patients with chronic muscle and metabolic diseases.
RejuverSen
This biotechnology firm develops senolytic therapies to eliminate senescent cells for treating cancer, fibrosis and age-related diseases in humans.
Integrated Biosciences
The company develops small-molecule therapies for age-related diseases using a synthetic biology and machine learning platform to target cellular stress responses.
